ALFA Finder| Management target | Revenue 11.0% FY27 |
|---|
| Revenue growth | 16% YoY growth driven by CDMO and new product launches. |
|---|---|
| Margins | EBITDA margin at 41.8% was boosted by one-time income. |
| Order book | Robust pipeline with 30 new high-potent API products. |
| Demand visibility | Strong demand in CDMO and specialized API segments across global markets. |
| Management confidence | High confidence in sustaining growth through pipeline execution and new facilities. |
Growth
Revenue grew 16% YoY; non-GPL business rose 20.8% and CDMO revenue jumped nearly 80% YoY.
Outlook
Management reaffirmed FY27 revenue growth guidance of 10-12% and EBITDA margins of 35-36%.
Risks
Normalization of high-margin new launch pricing and potential crude-led solvent cost escalation remain key risks.
Earnings Call Transcript filed with NSE, NSE: ALIVUS. Summary written with AI assistance from the document.
Alivus Life Sciences Ltd: key numbers
- Share price
- ₹1,480.60
- Market cap
- ₹18,207 Cr
- Revenue (annual)
- ₹2,552 Cr
- Net profit (annual)
- ₹564.5 Cr
- P/E (TTM)
- 27.2×Sector 43.0×
- Promoter holding
- 74.85%-0.02% QoQ
- FII holding
- 5.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alivus Life Sciences Ltd
All →Alivus Life Sciences Promoter Selling
Nirma Limited, a promoter of Alivus Life Sciences, sold 36,80,000 shares (2.99%) in the open market on 6 November 2026. Promoter holding falls from 74.73% to 71.74%.
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Alivus Life Sciences Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences Results Update
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Alivus Life Sciences Q2 FY27 Results: Net Profit ₹196.7 Cr, Up 51.3% YoY
Alivus Life Sciences Ltd reported revenue from operations of ₹682 Cr (+16.0% YoY) and net profit of ₹196.7 Cr (+51.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹196.7 Cr · +51.3% YoY
Alivus Life Sciences Board Meeting Date
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.